A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2017-11-03
Target enrollment:
Participant gender:
Summary
This is a study to determine the clinical benefit (how well the drug works), safety, and
tolerability of combining varlilumab and sunitinib. The study will enroll patients with
metastatic clear cell renal cell carcinoma.